or Try an Advanced Search...

    Stage Pharmaceutical Stocks List

    Symbol Grade Name % Change
    IKT A Inhibikase Therapeutics, Inc. 4.35
    CRNX B Crinetics Pharmaceuticals, Inc. 1.30
    CRMD B CorMedix Inc -0.65
    KPTI C Karyopharm Therapeutics Inc. -8.75
    ITRM C Iterum Therapeutics plc -5.43
    CASI C CASI Pharmaceuticals, Inc. -0.41
    HRMY D Harmony Biosciences Holdings, Inc. 2.96
    KALV D KalVista Pharmaceuticals, Inc. 3.31
    INM D InMed Pharmaceuticals Inc. -2.03
    SVRA D Savara, Inc. -0.96
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Pharmaceutical Disease Medicine Cancer Clinical Medicine Neurological Disorders Organ Systems Treatment Of Cancer Acromegaly Advanced Solid Tumors Aging Associated Diseases Angioedema Antibody Drug Conjugate Autoimmune Disease Biotechnology C1 Inhibitor CRM Cancer Treatment Cannabinoid Cannabis

    Related ETFs - A few ETFs which own one or more of the above listed Stage Pharmaceutical stocks.

    Symbol Grade Name Weight
    MNTL D Tema Neuroscience and Mental Health ETF 3.86
    HRTS D Tema Cardiovascular and Metabolic ETF 3.79
    SBIO B ALPS Medical Breakthroughs ETF 3.41
    PTH D Invesco DWA Healthcare Momentum ETF 1.77
    BBP A BioShares Biotechnology Products Fund 1.7
    View all Stage Pharmaceutical ETFs...
    Compare ETFs
    Compare HRTS to PTH Compare HRTS to SBIO Compare MNTL to PTH

        Stage Pharmaceutical Stocks Recent News

        Date Stock Title
        Nov 1 HRMY Earnings Beat: Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
        Nov 1 KPTI Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline
        Nov 1 CRMD While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate
        Oct 31 KPTI Karyopharm gains after changes to late-stage trial
        Oct 31 KPTI Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
        Oct 31 HRMY Harmony Biosciences Holdings Third Quarter 2024 Earnings: Beats Expectations
        Oct 31 KPTI Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
        Oct 31 KPTI Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
        Oct 31 HRMY Harmony Biosciences prices secondary offering at $31 per share
        Oct 31 CRMD Cormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses
        Oct 31 HRMY Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders
        Oct 30 KPTI Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
        Oct 30 CRMD CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript
        Oct 30 CRNX Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week
        Oct 30 CRMD CorMedix GAAP EPS of -$0.05 beats by $0.05, revenue of $11.46M beats by $0.62M
        Oct 30 CRMD CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update
        Oct 30 HRMY Harmony Biosciences Holdings Inc (HRMY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ...
        Oct 30 HRMY Q3 2024 Harmony Biosciences Holdings Inc Earnings Call
        Oct 29 HRMY Harmony Biosciences Holdings announces public offering
        Oct 29 HRMY Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Pharmaceutical Disease Medicine Cancer Clinical Medicine Neurological Disorders Organ Systems Treatment Of Cancer Acromegaly Advanced Solid Tumors Aging Associated Diseases Angioedema Antibody Drug Conjugate Autoimmune Disease Biotechnology C1 Inhibitor CRM Cancer Treatment Cannabinoid Cannabis
        Stage Pharmaceutical

        Stage Pharmaceutical is a biopharmaceutical company focused on developing innovative treatments for rare and neglected diseases. The company is developing a portfolio of novel therapies for rare and neglected diseases, including rare genetic disorders, rare cancers, and rare infectious diseases. Stage Pharmaceutical is committed to developing treatments that are safe, effective, and affordable for patients.

        Browse All Tags